Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.
The presence of measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in AML significantly predicts poorer survival outcomes, highlighting its potential as a critical MRD biomarker for risk stratif
Longitudinal analysis of 371 aplastic anemia patients reveals distinct patterns of clonal hematopoiesis under immunosuppressive therapy, highlighting variable mutation dynamics, cytogenetic changes, and progression risks.
CT0590, a novel allogeneic BCMA CAR T-cell therapy armored with NKG2A to resist host NK cell attacks, demonstrates promising safety and efficacy in relapsed/refractory multiple myeloma and plasma cell leukemia, addressing key transplant rej
The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive
This study reveals that CSNK1A1 E98 mutations in del(5q) MDS alter kinase signaling and metabolism, creating a stress-tolerant yet inflexible hematopoietic cell state with distinct clinical features and potential therapeutic vulnerabilities
This article explores the expression and functional impact of snoRNA-derived RNAs in healthy blood formation and acute myeloid leukemia, highlighting their potential as biomarkers and therapeutic targets.
Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant gastrointestinal graft-versus-host disease (GI-GVHD). Inhibition of the retinoic acid receptor restores steroid sensitivity and improves outcomes in murin
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.
This review synthesizes evidence on testicular endocrine function in boys undergoing treatment for hematological malignancies, highlighting reversible dysfunctions, Sertoli cell maturation delay, and the need for long-term endocrine surveil
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Routine DAT offers limited additional clinical value over transcutaneous bilirubin monitoring in low-risk ABO and RhD-incompatible neonates, supporting guideline shifts towards selective DAT use and emphasizing maternal antibody screening.
This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall
The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.
The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien
Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.
Septic shock following allogeneic hematopoietic stem-cell transplantation has a high 90-day mortality rate of 63%, strongly influenced by illness severity, fungal infection, and neutropenia. Early aminoglycoside use shows complex associatio
Cheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlighting
Distinct CAR architectures in tisa-cel (4-1BB costimulation) and axi-cel (CD28 costimulation) influence mechanisms of resistance through CD19 loss, affecting relapse rates in B-cell malignancies treated with CD19-CAR-T therapies.
Open language-specific specialty feeds and department pages.